Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification
Focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) are benign hepatocellular tumors. The risk of bleeding and malignant transformation of HCA are strong arguments to differentiate HCA from FNH. Despite great progress that has been made in the differential radiological diagnosis of the...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | International Journal of Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2013/268625 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552391778500608 |
|---|---|
| author | Charles Balabaud Wesal R. Al-Rabih Pei-Jer Chen Kimberley Evason Linda Ferrell Juan C. Hernandez-Prera Shiu-Feng Huang Thomas Longerich Young Nyun Park Alberto Quaglia Peter Schirmacher Christine Sempoux Swan N. Thung Michael Torbenson Aileen Wee Matthew M. Yeh Shiou-Hwei Yeh Brigitte Le Bail Jessica Zucman-Rossi Paulette Bioulac-Sage |
| author_facet | Charles Balabaud Wesal R. Al-Rabih Pei-Jer Chen Kimberley Evason Linda Ferrell Juan C. Hernandez-Prera Shiu-Feng Huang Thomas Longerich Young Nyun Park Alberto Quaglia Peter Schirmacher Christine Sempoux Swan N. Thung Michael Torbenson Aileen Wee Matthew M. Yeh Shiou-Hwei Yeh Brigitte Le Bail Jessica Zucman-Rossi Paulette Bioulac-Sage |
| author_sort | Charles Balabaud |
| collection | DOAJ |
| description | Focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) are benign hepatocellular tumors. The risk of bleeding and malignant transformation of HCA are strong arguments to differentiate HCA from FNH. Despite great progress that has been made in the differential radiological diagnosis of the 2 types of nodules, liver biopsy is sometimes necessary to separate the 2 entities. Identification of HCA subtypes using immunohistochemical techniques, namely, HNF1A-inactivated HCA (35–40%), inflammatory HCA (IHCA), and beta-catenin-mutated inflammatory HCA (b-IHCA) (50–55%), beta-catenin-activated HCA (5–10%), and unclassified HCA (10%) has greatly improved the diagnostic accuracy of benign hepatocellular nodules. If HCA malignant transformation occurs in all HCA subgroups, the risk is by far the highest in the β-catenin-mutated subgroups (b-HCA, b-IHCA). In the coming decade the management of HCA will be more dependent on the identification of HCA subtypes, particularly for smaller nodules (<5 cm) in terms of imaging, follow-up, and resection. |
| format | Article |
| id | doaj-art-ce56afe014604a2890a74101399614c6 |
| institution | Kabale University |
| issn | 2090-3448 2090-3456 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hepatology |
| spelling | doaj-art-ce56afe014604a2890a74101399614c62025-02-03T05:58:45ZengWileyInternational Journal of Hepatology2090-34482090-34562013-01-01201310.1155/2013/268625268625Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological ClassificationCharles Balabaud0Wesal R. Al-Rabih1Pei-Jer Chen2Kimberley Evason3Linda Ferrell4Juan C. Hernandez-Prera5Shiu-Feng Huang6Thomas Longerich7Young Nyun Park8Alberto Quaglia9Peter Schirmacher10Christine Sempoux11Swan N. Thung12Michael Torbenson13Aileen Wee14Matthew M. Yeh15Shiou-Hwei Yeh16Brigitte Le Bail17Jessica Zucman-Rossi18Paulette Bioulac-Sage19Inserm U1053, Université Bordeaux Segalen, 33076 Bordeaux Cedex, FranceInstitute of Liver Studies, King’s College Hospital, London, UKNational Taiwan University College of Medicine, Taipei, TaiwanDepartment of Pathology, University of California, San Francisco, CA 94143-0102, USADepartment of Pathology, University of California, San Francisco, CA 94143-0102, USADepartment of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USANational Taiwan University College of Medicine, Taipei, TaiwanInstitute of Pathology, University Hospital, 69120 Heidelberg, GermanyDepartment of Pathology, Yonsei University College of Medicine, P.O. Box 8044, Seoul, Republic of KoreaInstitute of Liver Studies, King’s College Hospital, London, UKInstitute of Pathology, University Hospital, 69120 Heidelberg, GermanyService d'Anatomie Pathologique, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, 1200 Brussels, BelgiumDepartment of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USADepartment of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, National University Hospital, National University Health System, 119074, SingaporeDepartment of Pathology, University of Washington School of Medicine, Seattle, WA, USANational Taiwan University College of Medicine, Taipei, TaiwanInserm U1053, Université Bordeaux Segalen, 33076 Bordeaux Cedex, FranceInserm, UMR-674, Génomique Fonctionnelle des Tumeurs Solides, IUH, 75010 Paris, FranceInserm U1053, Université Bordeaux Segalen, 33076 Bordeaux Cedex, FranceFocal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) are benign hepatocellular tumors. The risk of bleeding and malignant transformation of HCA are strong arguments to differentiate HCA from FNH. Despite great progress that has been made in the differential radiological diagnosis of the 2 types of nodules, liver biopsy is sometimes necessary to separate the 2 entities. Identification of HCA subtypes using immunohistochemical techniques, namely, HNF1A-inactivated HCA (35–40%), inflammatory HCA (IHCA), and beta-catenin-mutated inflammatory HCA (b-IHCA) (50–55%), beta-catenin-activated HCA (5–10%), and unclassified HCA (10%) has greatly improved the diagnostic accuracy of benign hepatocellular nodules. If HCA malignant transformation occurs in all HCA subgroups, the risk is by far the highest in the β-catenin-mutated subgroups (b-HCA, b-IHCA). In the coming decade the management of HCA will be more dependent on the identification of HCA subtypes, particularly for smaller nodules (<5 cm) in terms of imaging, follow-up, and resection.http://dx.doi.org/10.1155/2013/268625 |
| spellingShingle | Charles Balabaud Wesal R. Al-Rabih Pei-Jer Chen Kimberley Evason Linda Ferrell Juan C. Hernandez-Prera Shiu-Feng Huang Thomas Longerich Young Nyun Park Alberto Quaglia Peter Schirmacher Christine Sempoux Swan N. Thung Michael Torbenson Aileen Wee Matthew M. Yeh Shiou-Hwei Yeh Brigitte Le Bail Jessica Zucman-Rossi Paulette Bioulac-Sage Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification International Journal of Hepatology |
| title | Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification |
| title_full | Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification |
| title_fullStr | Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification |
| title_full_unstemmed | Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification |
| title_short | Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification |
| title_sort | focal nodular hyperplasia and hepatocellular adenoma around the world viewed through the scope of the immunopathological classification |
| url | http://dx.doi.org/10.1155/2013/268625 |
| work_keys_str_mv | AT charlesbalabaud focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT wesalralrabih focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT peijerchen focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT kimberleyevason focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT lindaferrell focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT juanchernandezprera focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT shiufenghuang focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT thomaslongerich focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT youngnyunpark focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT albertoquaglia focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT peterschirmacher focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT christinesempoux focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT swannthung focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT michaeltorbenson focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT aileenwee focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT matthewmyeh focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT shiouhweiyeh focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT brigittelebail focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT jessicazucmanrossi focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification AT paulettebioulacsage focalnodularhyperplasiaandhepatocellularadenomaaroundtheworldviewedthroughthescopeoftheimmunopathologicalclassification |